AxoGen Osake

AxoGen EV/FCF

EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) yhtiöstä AxoGen (AXGN) 23.7.2026 päivämäärällä on −356,87. Edellisenä vuonna EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) oli 155 791,09 — muutos −100,23 % (matalampi).

EV/FCF

−356,87

YoY

−100,23%

Viimeksi päivitetty:

EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) yhtiöstä AxoGen on 2026 −356,87 . EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) yhtiöstä AxoGen oli 2025 155 791,09 . Se laskee −100,23% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

AxoGen Osakeanalyysi

Mitä AxoGen tekee? AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life. AxoGen on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset AxoGen osakkeesta

Yhtiön AxoGen EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) on −356,87 vuonna 2026.

Access this data via the Eulerpool API

Arvostus — AxoGen

Kaikki tunnusluvut — AxoGen